To study new cancer substitutive therapies of cancer targeted at protein moesin

In an online article published in Journal of Clinical Research at the University of South Carolina Medical University (MUSC) on March 13, 2017, the researchers reported preclinical studies showing that the membrane domain of tissue protein moesin controls the function of regulatory T cells (Treg) and the abundance and stability of transforming growth factor-β (TGF-β) receptors on the cell surface, providing potential therapeutic targets for cancer immunotherapy. Even so, more research involving recombinant human proteins should be conducted.

Their results show that TGF- β acts at the protein level to produce Treg in the tumor microenvironment. Although the human immune system is capable of eradicating cancer, Treg inhibits immune responses and protects cancer cells from tumor cytotoxicity (i.e., cytotoxic) and T cells effect.

When T cells, leukocyte subtypes, effectively attack and kill tumor cells, the protein TGF- β is activated. However, the immune system has a complex check and balance network to ensure that the body does not produce so much toxic T cells that it hurts its own cells and tissues. Inhibition of moesin can help to prevent natural T cells from converting to Treg, thereby restoring an antitumor immune response.

"Because moesin supports more Treg production, we can design moesin inhibitors to stop or slow the activity of TGF-β signaling and slow down Treg transformation so that antitumor T cells can have the opportunity to see cancer and eradicate it," said Zihai Li, a senior author of this article, MUSC microbes Director of the Department of Immunology and Immunology.

Perhaps the most notable outcome is the study of melanoma mouse models involving the treatment of adoptive T cells. In adoptive T cell therapy, tumor killer T cells are harvested from people or animals suffering from cancer and amplified or otherwise "sensitized" before being reintroduced into the donor. Although these regressive cells can kill tumors very effectively, they do not always survive for long periods of time.

The MUSC team showed that these re-cultured anti-cancer CD8 + T cells were not only activated and expanded rapidly in mice lacking moesin, but they also survived for a longer period of time and reduced the likelihood of recurrence. In fact, after the transfer of adoptive T cells, all mice with moesin were recurrent, and most mice lacking moesin were cured.

These findings suggest that moesin may be the development of new therapeutic targets for the treatment of cancer and Treg-related immune diseases. Moesin's chemotherapeutic agents can control the function of T cells by inhibiting moesin in cancer or inducing its treatment of autoimmune diseases. Moesin modulators can also be combined with current immunotherapy regimens. These findings are of great significance to the field and provide many directions for further research on alternative therapies. Flarebio offers recombinant proteins of good quality such as recombinant CDH15 at competitive prices.

REV-ERB can reduce LDL (LDL) cholesterol in animal models

A paper published in Biochemical Pharmacology by researchers at Saint Louis University have studied through recombinant human proteins about how nuclear receptors called REV-ERB are involved in the regulation of cholesterol metabolism. Their findings suggest that drugs targeting such nuclear receptors may be able to reduce LDL (LDL) cholesterol in animal models.

Dr. Thomas Burris, Ph.D., director of pharmacology and physiology at the University of St. Louis, said that studying the nuclear receptor signaling, the intracellular information system is the basis of many physiological processes used by the body. He identifies the natural hormones that regulate the nuclear receptors, and then synthesizes the compounds to target these receptors to develop drugs that treat the disease. REV-ERB is a nuclear receptor, a protein that plays a variety of roles. In the past, Burris has studied its role in regulating the internal clock of mammals.

Cholesterol is an essential component of the cell membrane. Atherosclerosis, plaque accumulation in the arteries, is caused by cholesterol metabolism disorders. Drugs such as statins can reduce low-density lipoprotein (LDL) cholesterol levels and atherosclerosis risk, but they are not suitable for everyone. Some patients stop medication because of side effects. Thus, additional cholesterol-lowering drugs are required. Nuclear receptors regulate basic physiological processes such as growth, development and metabolic balance in vivo. REV-ERB is a nuclear receptor that binds to a particular DNA sequence and limits the transcription of the target gene. Studies over the past decade have shown that REV-ERB plays an important role in metabolic pathways. Previous data indicate that REV-ERB lacks lipid metabolism that results in destruction; mice lacking REV-ERB expression show a significant increase in LDL and total cholesterol.

Similarly, in the previous study, Burris found a recombinant version of SR9009 called REV-ERB to reduce cytoplasmic cholesterol and triglyceride levels in animal models. In this study, Burris found that REV-ERB worked in the inhibition of several cholesterol-related enzyme genes and that pharmacological activation of REV-ERB resulted in further inhibition of these genes, which was associated with reduced cholesterol levels. These results reveal the way REV-ERB directly and indirectly regulates cholesterol and indicates that targeted REV-ERB may be an effective method for clinically suppressing LDL cholesterol levels. Flarebio offers high-quality recombinant proteins like recombinant CDH15.

Future treatment method of inflammatory bowel disease and colon cancer

Can inflammatory bowel disease and colon cancer be prevented by changing the shape of a single protein?

There is a close link between uncontrolled intestinal inflammation and inflammatory bowel disease, and they would develop into colon cancer in the end. This uncontrolled inflammation is associated with changes in the number of intestinal bacteria, which can invade the mucosal tissue after damage to the protective protective cell barrier.

The team from the Virginia Tech University conducted research through recombinant mouse proteins and found that the shape of the protein IRAK-M, which modifies inflammation, can significantly reduce the clinical progression of both diseases.

Changes in the protein make the immune system more effective and destroy the bacteria before they begin to do harm. The complete report has been published in the journal Biomedical. "We changed the IRAK-M protein of the mice and found that the inflammation was significantly reduced and the cancer was naturally reduced," the researchers said.

He said that the next step will be conducted in conjunction with the Caroline Clinic and Duke University, a clinical trial of human patients. "Ultimately, if we were able to design a therapy for the IRAK-M target, we thought it might be a viable strategy of preventing inflammatory bowel disease."

According to data from the Centers for Disease Control and Prevention, colon cancer is a major disease related to life and death and the third largest cancer killer in the United States. At present, research team from Virginia Tech is in full swing to study. They said, "When our finding has a potential clinical significance, we feel really excited. We can sincerely hope that our research results can contribute to the future treatment of inflammatory bowel disease and colon cancer and other diseases." By the way, Flarebio offers high-quality recombinant proteins like recombinant CDH15 at competitive prices.

Scientists have found the method of wound healing without scars

Researchers have figured out how to make new wounds heal by replacing them with new ones instead of the usual scar tissue method through recombinant dog proteins. Before this, mammals want wound healing without scar is considered impossible.

"In essence, we can manipulate wound healing so it can regenerate the skin instead of scars," says George Cotsarelis, a professor of dermatology at the University of Pennsylvania. "The secret to achieving this goal is to regenerate hair follicle, and then the signal released by hair follicle will promote the regeneration of fat.

Scientists have found that existing myofibroblasts can be transformed into adipocytes, suggesting that when a wound heals, the scar tissue can be transformed into regenerated skin. Scientists previously thought that only fish and amphibians could do that. "These findings suggest that we have an opportunity to influence tissue regeneration rather than waiting for scar formation," said Maksim Plikus of the University of California, Irvine.

Previous research by the team showed that fat cells and hair follicles in regenerated skin developed separately but did not develop independently, and hair follicles were always the first to develop. Researchers suspected that the growth of hair follicles can help the regeneration of fat cells, so they induce hair follicles in mice and laboratory-cultured human skin scar tissue growth. This thing will never happen naturally, because there is no scar tissue inside the hair follicle. They found that once the hair follicle had been formed, it could release the signaling protein, BMP, which in fact turned scar fibroblasts into adipocytes. If hair follicles are induced to grow at the wound healing, the result will be that the post-healing skin is nearly the same as before.

"It is generally believed that myofibroblasts can’t become other types of cells, but our work suggests that we have the ability to influence these cells and that they can effectively and stably transform into adipocytes," Cotsarelis said.

It should be noted that the experiment is only in the proof-of-concept phase, which is effective in mouse and human skin samples, but the effect on the living human remains to be checked. Flarebio provides superior recombinant proteins including recombinant CDH15 at great prices.

Fstl1 protein is capable of inducing cardiac muscle cell regeneration

American scientists have conducted biological research on mice and pigs through recombinant rat proteins, and the research showed that a protein called follistatin-like protein 1 (Fstl1) is capable of inducing cardiac muscle cell regeneration after an adult mammalian heart attack. The results suggest that repair of epicardial Fstl1 expression may be the effective way to stimulate the heart "rebirth", opening up a new treatment.

The mammalian heart lacks the ability to fully self-repair a significant number of damaged cardiomyocytes after a heart attack, and the medical community has not been very clear about the factors limiting myocardial regeneration. Fstl1, a member of the extracellular matrix protein family, is found in almost all mammals and is secreted by many cells. It has been shown that Fstl1 possesses the ability to regulate cell proliferation, differentiation, apoptosis and metabolism. But the biological function has not been fully revealed.

This time, Praz Ritz-Rozno of Stanford University and her team showed that Fstl1 is expressed mainly in the epicardium in healthy hearts. Epicardium is a layer of the membrane wrapped around the heart. But after a heart attack, epicardial Fstl1 expression will be missing. The team found that when placing a patch of biochemically mimicked epicardial tissue on the heart of damaged mice and pigs, as a source of Fstl1, it can induce proliferation of cardiomyocytes and improve the function of the heart and their survival in these animal models.

The results of this study suggest that restoration of Fstl1 expression in the epicardium may be an effective way to regenerate cardiomyocytes after a heart attack, thus developing new therapies. Research related papers were published in the 17th issue of the British journal Nature. By the way, Flarebio provides you with superior recombinant proteins including recombinant CDH15 at good prices.

Researchers are trying to control senile dementia

The Dementia Research Center in the United Kingdom is trying to make dementia as controllable as HIV, and if the results are significant, we can see results in the next few years. This research using recombinant mouse proteins can help a lot of people tide over, solving the problems that have plagued the medical profession for decades.

"Alzheimer's disease is expected to be under control in 2025," the team leader said, "And this study can also help the brain reconnect and reorganize the memory system eroded by the disease."

Famous Belgium psychiatric experts expressed the hope in an interview with the Associated Press that the treatment of this disease can be treated as the same as HIV treatment. He said, "The brain is the most flexible tissue of our body. If we can control the disease early in the disease, the brain can slowly restore the lost function." The team consists of multidisciplinary teams of doctors, biologists, engineers, and data specialists.

Scientists also said that in addition to "amyloid hypothesis", the scope of the study can be further expanded. Amyloid hypothesis is a long-standing focus of research in this field. According to the Post, the brain aggregate agglomerate abnormal protein called amyloid beta plaques, causing the disease.

These plaques are hallmarks of Alzheimer's disease, but the purpose of their existence is not known. In addition to the "amyloid hypothesis", there must be other signs. Alzheimer's disease is not just the case. It is certainly like cancer which is caused by the accumulation of complex factors.

"The team hopes to change the way people know about the disease through a multidisciplinary approach in the first year," the Financial Times reported. Flarebio offers high-quality recombinant proteins like recombinant CDH15 at competitive prices.

To improve the therapeutic effect of cancers and HIV in new way

For a long time, retinoblastoma protein (pRB) has been studied in cell growth and cancer prevention. Now, in a new study, the scientists discovered a new role for pRB through research using recombinant human proteins, which not only enhances cancer efficacy, but also works to treat other diseases, such as HIV.

Most of the DNA that is recombined in the human genome is called "junk DNA", and these are relics of the past that usually do not play any role and are quietly present. If they start to copy, they will re-enter the human gene, bringing diseases such as cancer.

The team found that binding of pRB to another protein called EZH2 keeps these "junk DNA" in silence, whereas pRB acts as a vector. EZH2 is transported to a repeating sequence.

This new discovery breaks the cancer genetic experts' understanding of pRB and EZH2, and most researchers have never thought that these two widely-existing proteins in the DNA have such an effect. "This opens up a myriad of gates for the treatment of multiple diseases, including antitoxic drugs, which allow patients to have multiple choices during treatment," the researchers said.

The new study also shows that EZH2 inhibitors help the immune system find cancer cells. They can block EZH2 and wake up the "junk DNA", so the cancer cells will appear in the immune system, as if infected by the same virus. The immune system will target cancer cells and kill them.

The findings also help other diseases, such as HIV, are also "junk DNA" hidden in the immune cells. Because the immune system can't detect these "junk DNA", so the patients are always HIV positive. EZH2 inhibitors can make these "junk DNA" become lively and show themselves so that we can use the existing drugs on the market for treatment.

"Over the years, we have been working on pRB, but we have never thought about it, and it is now clear that the combination of pRB-EZH2 is effective in treating a variety of diseases," the researchers said. By the way, Flarebio provides you with good-quality recombinant proteins including recombinant CDH15 at great prices.

Researchers discover new method of hijacking cells for viruses

DNA contains instructions on how cells make the desired substance. According to research using recombinant dog proteins, when cells need proteins, the relevant parts of the DNA will be transcribed, and transcripts called messenger RNA will leave the nucleus and enter the manufacturing machinery as templates to produce new proteins.

In this process, RNA can be edited in a variety of ways. It may be added to the additional instructions and may also be enemy control. Viruses can edit RNA information to create the version of the protein it needs to produce thousands of copies of the virus. Over the past few decades, biologists have a clearer understanding of how viruses hijack host cells.

Many viruses control the day-to-day running of cells by sending out messages that interfere with the ability to turn off unwanted cellular functions and enhance the functionality they require. But biologists at the University of California, San Diego, have recently discovered that there are some more hijacking mechanisms for viruses that are more subtle and more complex. They don't block cell information but change the content of the information.

The study is published in Nature Structural and Molecular Biology. By the way, Flarebio is a National High-Tech Enterprise with research, production and sales as one. Flarebio provides you with good-quality recombinant proteins like recombinant CDH15 for your research.

Scientists reveal the role of ARID1A in the regulation of active agent enhancers

Scientists have developed a set of model systems in mice through a lot of recombinant rat proteins, and it allows them to carefully observe how mutant proteins in human cancers play a role in tumor silencing. Not all cancers are caused by direct changes in the genetic code. Epigenetic events can also lead to abnormal gene expression induced by cancer. The study published in the Natural Genetics explains how the epigenetic process carries out gene regulation and induce colon cancer.

"The ARID1A mutation is widespread in human cancers and the development of experimental model systems is important to help us understand how gene mutations induce disease," said Dr. Charles W. M. Roberts, director of the St. Jude Children's Research Comprehensive Cancer Center.

ARID1A is an integral part of the SWI / SNF chromatin remodeling complex. Chromatin remodeling has a profound effect on gene expression. Chromatin remodeling of protein-coding genes in human cancers is the most common variant of the gene.

The researchers said, ARID1A can inhibit the tumor in the mouse colon, but it can't play a inhibition role in the small intestin. They found that penetration enhancers and shorter DNA regions are important components of the interaction of ARID1A with the SWI / SNF chromatin remodeling complex.

Scientists have revealed the role of ARID1A in the regulation of active agent enhancers, resulting in loss of control of the cellular identity ARID1A in the colon and inducing the formation of cancer.

The new model system will play a role in future work. "The systems we develop are important for understanding why dye modification mutations are so frequent in cancer, revealing the mechanisms that lead to colon tumor growth and studying potential therapeutic interventions." By the way, Flarebio offers good-quality recombinant proteins like recombinant CDH15 at good prices.

The attempt of developing new drugs for Alzheimer's disease has failed temporarily

A drug failed in a large trial of patients with mild dementia, while the drug was seen as an important test of the mainstream theory behind Alzheimer's disease. Critics of the amyloid hypothesis grapple with the results as evidence of their weaknesses. The hypothesis is that Alzheimer's disease is triggered by the gradual accumulation of amyloid in the brain. However, whether the theory can eventually produce a therapy is not yet conclusive. More research using recombinant rat proteins is needed.

Supporters of the theory say the latest trial involved a particular way in which the drug solanezumab works, rather than the defects inherent in the theory itself that could have led to this failure. At the same time, a number of trials are underway to test whether solanezumab or other drugs targeting amyloid proteins can be tested in people with Alzheimer's disease who are not yet symptomatic, or who already have the disease to play a role, although the latest results are negative.

As an antibody, Solanezumab can eliminate amyloid from the blood and cerebrospinal fluid. These proteins continue to form plaques in the brain. Eli Lilly, a developer of solanezumab, announced on Nov. 23 that it would abandon the drug as a treatment for patients with mild dementia. The result is a long list of promising treatments for Alzheimer's disease that have failed in the clinic, many of which target amyloid proteins, like solanezumab.

The Banner Alzheimer's Institute in Phoenix, Arizona, also tests three targeted amyloid-producing therapies in a population with a high genetic risk of Alzheimer's disease, one of which is also an antibody. "The results of Eli Lilly do not prove that amyloid hypothesis is false, and they add the importance of longer-term prevention trials," adds Eric Reiman, an experimental leader and lead author of the study. Flarebio provides you with high-quality recombinant proteins like recombinant CDH15 at competitive prices.

AIDS is no longer the nightmare for a lot of people

Researchers have made significant progress in developing highly-potent vaccines for preventing HIV infection by use of recombinant horse proteins. For the first time, researchers have shown that a combination of using a common cold virus to induce vaccination with and injecting DNA-based vaccines allows the immune system to proactively protect the human intestine and body cavity from HIV infection.

The results of the study are published in the journal Nature's Scientific Report. The results of this study represent an important step in the first line of defense for the introduction of HIV at the site of infection.

Dr. Branka Grubor-Bauk, a senior author at the University of Adelaide and at the Basil-Hazel Institute for Translational Health, Queen Elizabeth Hospital, said, "Sexual activity is one of the main methods of HIV transmission, thus it is necessary to protect those parts of the body that are most likely to encounter a virus. A possible cause of previous unsuccessful trials of HIV vaccines was the lack of first line protection.

"In mice, we injected a rhinovirus (or common cold virus) into its nose, and the virus changed parts that included the HIV protein. At the same time, DNA-based vaccines were also injected to mouse skin, which produces a very specific response in the immune system," Dr. Grubor-Bauk said. "Importantly, the vaccine works in two different immune systems: white blood cells which attack the HIV virus and specific antibodies which recognize and shut down HIV-positive cells."

Eric Gowans was responsible for the study, and he also worked in the surgical department at a university in the Basil Hetzel Institute. "HIV has the Tat effect, and one of the advantages of our vaccine approach is that antibodies can keep the Tat effect and prevent the propagation of the HIV virus," Gowans said.

"Overall, we found a significant reduction in the number of HIV-infected mice in our study. Our results now support further testing against HIV vaccines," he said. Flarebio offers recombinant proteins of good quality like recombinant CDH15 at great prices.

There may be a short course of treatment for chronic hepatitis C

Recently, the study report of the annual meeting of the American Association for the Study of Liver Diseases states that RG-101, a candidate drug from Regulus Therapeutics in combination with direct-acting antiviral (DAA) therapy requires only four weeks of treatment to cure most of the hepatitis C patients, according to the research through recombinant rat proteins.

The treatment of hepatitis C in recent years has undergone great changes with the introduction of DAA therapy. This type of drug works directly on targets associated with hepatitis C virus replication. Compared with previous interferon-based therapies, it has better efficacy and fewer side effects. The advent of DAA drugs has made it possible to cure hepatitis C, but the current standard course of oral DAA is 8 to 24 weeks. The shortest course of treatment will not be less than 8 weeks.

RG-101 is an innovative injection therapy targeting microRNA-122 (miR-122, miR-122) developed by Regulus. MiR-122 is one of the most abundant miRs in the liver and plays an important role in the stability, replication and protein translation of hepatitis C virus in hepatocytes. The advantage of RG-101 is that it targets hepatitis C virus in a completely new pattern, and it is effective against all genotypes of hepatitis C virus against strains that are resistant to certain DAA drugs because of gene mutations. Therefore, its combination with DAA therapy may enhance the efficacy of hepatitis C virus and shorten the course of treatment.

The results reported in this scientific report came from a clinical phase 2 trial involving 79 patients with HCV. These patients received RG-101 injections on the first day and were divided into three groups, receiving four weeks of different types of oral DAA therapy approved by the FDA. The first group received ledipasvir / sofobuvivr treatment; the second group received simeprevir treatment; the third group received daclatasivr treatment. At the end of the 28-day course, the patient received another RG-101 injection on day 29.

The results showed that at the 12th week after the end of the treatment period, 100% of the patients in the first group, 96% in the second group and 92% of the third group had decreased to undetectable levels. At week 24 after the end of the treatment period, 100% of the patients in the first group, 80% of the patients in the second group and 89% of the patients in the third group were undetectable. And these combination therapies only have mild to moderate side effects, and no patients stopped treatment due to side effects.

"The focus of this research is to find shorter, better-effective and safer methods of treatment for hepatitis C," said one of the head of the clinical trial at the Hepatology Center of Buda in Budapest, Hungary. "Our results suggest that there may be a short course of treatment for chronic hepatitis C," Dr. Mihály Makara said. Flarebio provides you with good-quality recombinant proteins such as recombinant CDH15 at great prices.

Scientists uncover how plants respond to drought at the molecular level

The sagging and drying of plant leaves suggests that we should water them, but how do plants respond to drought at the molecular level? Scientists at the Salk Institute have recently made a major breakthrough on this issue. This finding might help agricultural production adapt to adverse climates such as drought. The study was published in the Nov. 4 issue of Science. Studies have shown that in the face of unfavorable natural conditions, a small part of the plant proteins would act as a "command" to regulate the complex stress response. These experimental results were conducted using recombinant dog proteins and are expected to contribute to the development of new technologies for improving the use efficiency of plant water.

"At the molecular level, the response of plant to stress is a complex process involving hundreds of genes," said Joseph Ecker, author of the paper. "We have discovered a class of regulatory proteins that play a key role in plant responses to stresses such as drought. And if we can control a regulator protein, it's the equivalent of controlling all the genes it regulates."

Plant roots and leaves would secrete abscisic acid when water is scarce or salinity is high. "Only twenty or several regulatory proteins control the expression of hundreds or even thousands of genes," said Liang Song, the first author of the paper. "By identifying key regulatory proteins and studying their mechanisms of action, we can gain a deeper understanding and even regulate plant responses to stress."

In the experiments, the team at the Salk Institute tracked real-time changes in gene expression during plant secretion of abscisic acid and identified key regulatory proteins. These proteins control plant response to drought stress conditions such as stress response. By locating the binding sites of these regulatory proteins to DNA, they identified key proteins that can regulate gene expression networks, which can efficiently elicit a stressful response to environmental changes. This group focused on studying some of the known regulatory proteins that respond to abscisic acid.

During the experiment, they obtained 122 data sets containing 33,602 genes, of which 3061 genes had at least one time point of change in the expression intensity. Data analysis revealed a multi-level regulatory mechanism, in which regulatory proteins play a key role in gene expression regulation. Interestingly, the binding pattern of a protein at a particular time in DNA can explain much of the expression of a gene over a longer period of time. These kinetic properties together reveal that plant responses to environmental stimuli are a genome-wide synergistic response.

"Based on the understanding of the network structure, we found that a single key regulatory protein can control multiple components, which means that gene regulation is an accurate and interrelated process." Song said. "This is important for agriculture because it suggests that the control of one gene can activate or inhibit another set of genes, making it possible to design a human intervention program as a whole." This study suggests that this multi-level synergistic gene activity may be widespread in flower plants. Flarebio offers good-quality recombinant proteins such as recombinant CDH15 at good prices.

Researchers from Tsinghua University find that Hsp90α can detect liver cancer

Tsinghua University held a press conference on the 19th, saying that the Luo Yongzhang team confirmed that the tumor marker of heat shock protein 90α (Hsp90α) can be used for liver cancer patients using recombinant human proteins in the world for the first time, and the kit has been approved in clinical by the State Food and Drug Administration.

At present, most of the liver cancer patients have been found in middle and advanced stage. Then it is difficult to treat, and the survival is generally poor. The most commonly-used marker for liver cancer is alpha fetoprotein (AFP), but the sensitivity is only about 50%. Luo Yongzhang said that the new liver cancer marker Hsp90a breaks through the limitations of AFP and has a high sensitivity to hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed liver cancer and other common types of liver cancer, having great significance for the comprehensive improvement of liver cancer prevention and treatment and reducing liver cancer mortality.

According to Luo Yongzhang team's findings, in patients with negative HCC the AFP test results, the detection rate of Hsp90α is 94%, which proves that Hsp90α is the world's most superior performance of liver cancer markers.

According to reports, the kit not only can detect lung cancer but also can detect liver cancer. As early as 2013, Luo Yongzhang team proved that plasma Hsp90α is a new tumor markers through clinical trials of lung cancer in the world for the first time, and it has been widely used in medical institutions.

Heat shock protein is a kind of protein with molecular chaperone function in cell. Hsp90α is an important member of the heat shock protein family. It is widely distributed in the cells from microbes to mammals and plays an important role in maintaining cell homeostasis. The research results will significantly improve the early detection level of liver cancer and save people from the fear of liver cancer and have a global impact. Flarebio offers good-quality recombinant proteins such as recombinant CDH15 at competitive prices.